Tag: Sentynl Therapeutics
Sentynl Therapeutics, a Zydus Group company announces global acquisition of Zokinvy
Zokinvy is approved in the US, European Union and Great Britain, and Japan for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients
BridgeBio & Sentynl Therapeutics get EU nod for NULIBRY, a therapy...
MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years
Zydus subsidiary supported drug data for Menkes disease set to be...
Fortress Biotech and Cyprium Therapeutics alongwith Zydus Lifesciences’ Sentynl Therapeutics announce CUTX-101, copper histidinate data to be presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting